NPAS2 and hepatocellular carcinoma: have shown that NPAS2 polymorphisms are associated with the death risk of HCC patients after transcatheter arterial chemoembolization treatment.39 In line with these findings, we found that rs11133399 in CLOCK, rs1044432 and rs2279284 in BAML1 are significantly associated with the prognosis of GC patients.